Last updated: August 4, 2025
Introduction
Patent DK2214679, filed by Neurelis, Inc., in Denmark, pertains to a pharmacological invention related to the treatment or prevention of neurological or psychiatric conditions using a specific pharmaceutical formulation. This patent holds significance within the broader landscape of neuropsychiatric treatment patents, especially considering its focus on innovative formulations for active pharmaceutical ingredients (APIs).
This analysis aims to dissect the scope and claims of DK2214679, contextualize it within the existing patent landscape, and evaluate its strategic implications for stakeholders in neuropharmacology and drug development.
Scope of Patent DK2214679
The scope of a patent defines the extent of legal protection conferred by the claims, outlining what is and isn't covered. DK2214679 appears to focus on a specific pharmaceutical formulation, potentially involving novel compositions, methods of administration, or use of APIs for neuropsychiatric indications.
Key elements of the patent scope include:
- Composition of matter: Likely encompasses a novel formulation involving a specific active ingredient or combinations thereof.
- Method of use: May claim methods for treatment or prophylaxis of neurological conditions using the formulation.
- Administration route: Possibly specifies targeted administration modalities (e.g., nasal, oral, transdermal).
- Dosage forms and excipients: Could include stable, bioavailable, or controlled-release formulations.
Given the nature of such patents, the scope is often deliberately broad to safeguard various embodiments, yet sufficiently precise to withstand legal scrutiny.
Claims Analysis
The core of patent enforceability lies in its claims. They delineate the legal boundaries of protection. While the actual granted claims can be complex, typical claims in such patents focus on:
1. Composition Claims
- Broad Composition Claim: Likely covers a pharmaceutical formulation comprising a specific active compound (e.g., a benzodiazepine, neurosteroid, or novel therapeutic agent) combined with specific excipients or carriers.
- Narrow Composition Claims: Possible claims limited to certain concentrations, salts, crystalline forms, or formulations with particular stability or bioavailability features.
2. Method of Treatment Claims
- Therapeutic Use: Claims may describe methods of administering the formulation to alleviate symptoms of neurological or psychiatric diseases—such as epilepsy, anxiety, or mood disorder.
- Prophylactic Use: Could cover preventive applications in high-risk patient populations.
3. Manufacturing and Formulation Claims
- Preparation Process: Claims could include processes for manufacturing the pharmaceutical composition, emphasizing stability or controlled-release features.
- Specific Formulations: Claims may specify particular excipient combinations, particle sizes, or delivery systems to enhance bioavailability or patient compliance.
4. Use Claims
- New Use of Known Compounds: Claims may be directed towards the novel therapeutic applications of known APIs, a common strategy to expand patent coverage beyond compound claims alone.
In summary, DK2214679's claims appear structured to encompass a broad spectrum of pharmaceutical compositions and their therapeutic applications, with detailed specifications ensuring coverage of multiple embodiments.
Patent Landscape for DK2214679
An understanding of the patent landscape involves situating DK2214679 within existing patent portfolios, identifying overlapping claims, and assessing potential freedom-to-operate risks.
1. Prior Art and Related Patents
The neuropharmacology domain is heavily crowded, with patents often focusing on:
- Active pharmaceutical ingredients: Benzodiazepines, neuropeptides, or novel synthetic compounds.
- Formulation innovations: Controlled-release matrices, nasal sprays, transdermal patches.
- Methodologies: Novel administration routes or therapeutic indications.
Key prior art references likely include patents on formulations for psychiatric disorders, such as:
- US patents regarding benzodiazepine formulations (e.g., USXXXXXXX)
- European patents focusing on nasal delivery systems for neuroactive agents.
2. Overlapping IP and Freedom to Operate
Analysis suggests that DK2214679 may intersect with:
- Existing formulations for neuropsychiatric drugs, especially if similar active ingredients or delivery methods are involved.
- Method-of-use patents that claim novel therapeutic indications, which might buffer or extend the patent's protection scope.
3. Patent Family and Regional Coverage
While DK2214679 is a Danish patent, its family members may extend protection across Europe via the European Patent Convention (EPC) and internationally through PCT routes.
Implications:
- Regional patent rights could be a strategic asset, blocking competitors in Europe.
- Potential overlaps with existing regional patents need careful navigation.
4. Validity and Enforceability Considerations
- Broad claims that are not adequately supported by experimental data may face invalidation challenges.
- The patent's inventive step must be sufficiently distinguished from prior art.
- Its lifespan is typically 20 years from the priority date, offering long-term market exclusivity if maintained.
Strategic Implications of the Patent Landscape
DK2214679’s positioning largely depends on:
- Its ability to claim novel, non-obvious formulations or uses.
- The extent of prior art in similar delivery systems for neuropharmaceuticals.
- Its alignment with regional patent protections to prevent third-party infringement.
Given the complex and crowded patent space in neurotropic pharmaceuticals, strategic patent prosecution and potential continuation applications may enhance its defensive and offensive IP positioning.
Conclusion
Scope and Claims Summary:
DK2214679 protects a pharmaceutical formulation and potentially its methods of use and manufacturing, tailored toward neurological or psychiatric indications. Its claims are designed to cover multiple embodiments, including composition, method, and formulation innovations.
Patent Landscape Summary:
The patent exists within a dense environment of neuropharmacological patents, with significant overlaps in formulation types, APIs, and delivery methods. It likely benefits from regional protections in Denmark and Europe, with potential extensions via family members. The patent’s strength hinges on the novelty, inventive step, and clear differentiation from prior art.
Business Takeaway:
Stakeholders should carefully map existing IP landscapes to avoid infringement and identify opportunities for licensing or designing around such patents. For innovators, DK2214679 underscores the importance of strategic patent drafting, especially in complex therapeutic areas with established prior art.
Key Takeaways
- DK2214679 covers specific pharmaceutical compositions and methods that are strategically significant within neuropsychiatric treatment domains.
- Its claims are broad but must be supported by robust data to withstand validity challenges.
- The patent landscape in neuropharmacology is highly competitive, necessitating thorough freedom-to-operate analyses.
- Regional protections enhance the patent’s commercial value, but overlapping prior art requires ongoing vigilance.
- Innovators should consider patent prosecution strategies that focus on groundbreaking formulations or uses to create strong boundary claims.
FAQs
-
What is the primary focus of DK2214679?
It pertains to a novel pharmaceutical formulation and therapeutic methods for treating neurological or psychiatric conditions.
-
How broad are the claims of DK2214679?
The claims likely encompass a wide range of compositions, methods of use, and manufacturing processes, designed to cover various embodiments of the invention.
-
What is the patent landscape like for neuropsychiatric drug formulations?
The landscape is highly competitive, featuring overlapping patents on APIs, delivery systems, and therapeutic uses, which necessitates strategic IP management.
-
Can DK2214679's claims be challenged or invalidated?
Yes, if prior art demonstrates that the claims are obvious or not novel, invalidation could follow. However, well-drafted claims supported by experimental data are more resilient.
-
How does regional patent protection impact the patent's enforceability?
Regional protections, such as in Denmark and broader Europe, enhance enforceability but also require monitoring for infringing activities within those jurisdictions.
References
[1] European Patent Office (EPO) Patent Database, DK2214679.
[2] GlobalData, Neuropharmacology Patent Landscape Report, 2022.
[3] WIPO PatentScope, Patent Family Analysis for Neuropsychiatric Formulations.
